The implications of thromboembolism in chronic heart failure
Ambăruş, V.; Rezuş, C.; Ghiuru, R.; Ionescu, S.; Manea, P.; Leuciuc, E.; Artenie, R.; Sandru, V.; Cosovanu, A.
Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 106(1): 107-111
2002
ISSN/ISBN: 0048-7848 PMID: 12635370 Document Number: 10122
The goal of investigation was to determine whether long-term anticoagulant therapy influences the mortality rate in CHF. The method consisted in the calculation of the annual death rate of the patients with CHF class III-IV NYHA: group A (controls)--who did not receive anticoagulant or antiplatelet therapy; group B--treated with Acenocumarol or Aspirin. The results show in group A, which included 150 patients, during the 5-year interval under study 30 deaths, representing an annual death rate of 4%. In group B, which included 325 patients of which 75 treated with Acenocumarol and 250 patients with aspirin, 20 deaths were recorded during the same 5-year interval, representing an annual death rate of 1.2%. Thus, the mortality risk proved to be 70% lower in group B than in the control group. It came out that the main mechanism of death in CHF is thrombembolism and in this circumstance anticoagulant or antiplatelet therapy would be essential.
Document emailed within 1 workday
